Niraparib | MK-4827 | MK-4827( 尼拉帕尼) | PARP | AmBeed-信号通路专用抑制剂

首页 / / / PARP / Niraparib

尼拉帕尼 /Niraparib {[allProObj[0].p_purity_real_show]}

货号：A298513 同义名： MK-4827( 尼拉帕尼) / MK-4827

Niraparib（MK-4827）是一种高效、口服生物利用度的PARP1和PARP2抑制剂，其IC50分别为3.8 nM和2.1 nM。尼拉帕尼抑制DNA损伤修复，激活凋亡，并显示出抗肿瘤活性。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Niraparib 化学结构
CAS号：1038915-60-4

Niraparib 3D分子结构
CAS号：1038915-60-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Niraparib 纯度/质量文件产品仅供科研

货号：A298513 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell Host Microbe, 2024. Ambeed. [ A163338 ]; • Cancer Res., 2024. Ambeed. [ A295334 ]; • J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]; • J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]; • JBC, 2024, 107935. Ambeed. [ A194396 ]; 更多 >

PARP 亚型比较

产品名称	PARP ↓ ↑	PARP1 ↓ ↑	PARP2 ↓ ↑	PARP3 ↓ ↑	纯度
PJ34 HCl	++ PARP, EC50: 20 nM				99%+
Rucaparib phosphate	++++ PARP, Ki: 1.4 nM				99%+
3-Aminobenzamide	++ PARP, IC50: <50 nM				98%
AZD-2461	✔				99%+
BGP-15	✔				99%+
NU1025	+ PARP, IC50: 400 nM				97%
Benzamide	+ PARP, IC50: 3.3 μM				98%
Picolinamide	+ PARP, IC50: 95 μM				98%
AG14361		+++ PARP1, Ki: <5 nM			98+%
Iniparib		✔			98%
Talazoparib		++++ PARP1, IC50: 0.57 nM			99%+
NMS-P118		++ PARP1, Kd: 0.009 μM			98+%
UPF 1069		+ PARP1, IC50: 8.0 μM	++ PARP2, IC50: 0.3 μM		98%
A-966492		++++ PARP1, EC50: 1 nM PARP1, Ki: 1 nM	+++ PARP2, Ki: 1.5 nM		99%+
Veliparib		++ PARP1, Ki: 5.2 nM	+++ PARP2, Ki: 2.9 nM		98%
Niraparib tosylate		+++ PARP1, IC50: 3.8 nM	+++ PARP2, IC50: 2.1 nM		99%+
Stenoparib		++++ PARP1, IC50: 1 nM	++++ PARP2, IC50: 1.2 nM		98%
Olaparib		+++ PARP1, IC50: 5 nM	++++ PARP2, IC50: 1 nM		98%
Niraparib		+++ PARP1, IC50: 3.8 nM	+++ PARP2, IC50: 2.1 nM		98%
ME0328		+ PARP1, IC50: 6.3 μM		+ PARP3, IC50: 0.89 μM	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Niraparib 生物活性

靶点	PARP1 PARP1, IC50:3.8 nM PARP2 PARP2, IC50:2.1 nM
描述	PARP1, also called as Poly(ADP-ribose) polymerase, is involved in the signaling of DNA damage. It can recognize and bind DNA single or double-strand breaks, thus possessing various cellular function, including regulation of apoptosis and chromosome stability, gene amplification and transcription, as well as cell division and differentiation. PARP-2 is the closest homolog of PARP1 (~62% similarity in catalytic domain) and compensates for PARP-1 activity in DNA single-strand break. MK-4827 is potent inhibitor of PARP1 and PARP2 with IC50 values of 3.8nM and 2.1nM (measured by PARP isoform TCA assays), respectively, at least a 100-fold selectivity over PARP-3, V-PARP, and tankyrase-1. MK-4827 inhibited PARP activity with EC50 of 4nM and preferentially suppressed proliferation of MDA-MB-436 cells carrying BRCA-1 mutation with CC50 value of 18nM and CAPAN-1 cells carrying BRCA-2 mutantation with CC50 value of 90nM. Oral treatment with MK-4827 at either 100 mg/kg q.d. or 50 mg/kg b.i.d. for 33 days repressed tumor growth in a BRCA-1 mutant MDA-MB-436 xenograft model^[1].Oral administration of MK-4827 at a dose of 50mg/kg once daily radiosensitized all four tumors regardless of the p53 status, including Calu-6, H460, A549 and MDA-MB-231, with reduced PAR levels in tumors^[2].
作用机制	MK-4827 is a nicotinamide derivate, which can compete with NAD+ for the PARP catalytic site.^[3]

Niraparib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
A2780 cells		Function assay		Inhibition of PARP in human A2780 cells assessed as inhibition of hydrogen peroxide-induced PARylation by cell-based assay	25761096
A549 cells		Cytotoxicity assay	5-7 days	Cytotoxicity against human A549 cells transfected with BRCA2 shRNA assessed as inhibition of cell proliferation after 5 to 7 days by CellTiter-Blue assay, CC50=0.011 μM	25761096
BT20 cells		Cytotoxicity assay	5-7 days	Cytotoxicity against human BT20 cells assessed as inhibition of cell proliferation after 5 to 7 days by CellTiter-Blue assay, CC50=2.2 μM	25761096
Capan1 cells		Cytotoxicity assay		Cytotoxicity against BRCA2-deficient human Capan1 cells, CC50=0.09 μM	25761096

Niraparib 动物研究

Dose	Rat^[4]: 3 mg/kg (i.v.), 5 mg/kg (p.o.) Mice: 25 mg/kg, 50 mg/kg^[2] (p.o.), 100 mg/kg^[2] (p.o.)
Administration	i.v., p.o.

Niraparib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03705156	Platinum-sensitive Relapsed Ov... 展开 >>arian Cancer 收起 <<	Phase 3	Recruiting	June 8, 2020	-
NCT03709316	Ovarian Cancer	Phase 3	Recruiting	June 30, 2021	-
NCT03574779	Ovarian Cancer	Phase 2	Recruiting	June 2020	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, Oklahoma Stephenson Cancer Center Recruiting Oklahoma City, Oklahoma, United States, 73104 收起 <<

Niraparib 参考文献

[1]Jones P, Altamura S, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.

[2]Wang L, Mason KA, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30(6):2113-20.

[3]Javle M, Curtin NJ, et al. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol. 2011 Nov;3(6):257-67.

Niraparib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.12mL

0.62mL

0.31mL

15.61mL

3.12mL

1.56mL

31.21mL

6.24mL

3.12mL

Niraparib 技术信息

CAS号	1038915-60-4
分子式	C₁₉H₂₀N₄O
分子量	320.39

别名	MK-4827( 尼拉帕尼) ;MK-4827
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,2-8°C

溶解度

DMSO: 25 mg/mL(78.03 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 1 mg/mL clear

PO 0.5% CMC-Na 40 mg/mL suspension

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03705156	Platinum-sensitive Relapsed Ov... 展开 >>arian Cancer 收起 <<	Phase 3	Recruiting	June 8, 2020	-
NCT03709316	Ovarian Cancer	Phase 3	Recruiting	June 30, 2021	-
NCT03574779	Ovarian Cancer	Phase 2	Recruiting	June 2020	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, Oklahoma Stephenson Cancer Center Recruiting Oklahoma City, Oklahoma, United States, 73104 收起 <<
NCT03598270	Recurrent Ovarian Carcinoma	Phase 3	Not yet recruiting	November 2023	Spain ... 展开 >> Complejo Hospitalario Universitario de A Coruña Not yet recruiting A Coruña, Spain Contact: María Quindós, MD Principal Investigator: María Quindós, MD ICO Badalona Not yet recruiting Badalona, Spain Contact: Margarita Romeo, MD Principal Investigator: Margarita Romeo, MD H. Clínic Barcelona Not yet recruiting Barcelona, Spain Contact: Lydia Gaba, MD Principal Investigator: Lydia Gaba, MD Hospital de la Santa Creu i Sant Pau Not yet recruiting Barcelona, Spain Contact: Cristina Martin, MD Principal Investigator: Belén Ojeda, MD Hospital de la Vall d'Hebron Not yet recruiting Barcelona, Spain Contact: Ana Oaknin, MD PhD Principal Investigator: Ana Oaknin, MD PhD H Reina Sofía Cordoba Not yet recruiting Cordoba, Spain Contact: Maria Jesus Rubio, MD Principal Investigator: Maria Jesus Rubio, MD ICO Girona Not yet recruiting Girona, Spain Contact: Pilar Barretina, MD Principal Investigator: Pilar Barretina, MD ICO Hospitalet Not yet recruiting Hospitalet del Llobregat, Spain Contact: Beatriz Pardo, MD Principal Investigator: Beatriz Pardo, MD Hospital de León Not yet recruiting León, Spain Contact: Luis Miguel de Sande, MD Principal Investigator: Luis Miguel de Sande, MD Clinica Universitaria de Navarra Not yet recruiting Madrid, Spain Contact: Antonio Gonzalez, MD PhD Principal Investigator: Antonio González, MD PhD Hospital Clínico San Carlos Not yet recruiting Madrid, Spain Contact: Gloria Marquina, MD Principal Investigator: Gloria Marquina, MD Hospital Gregorio Marañon Not yet recruiting Madrid, Spain Contact: Sara Pérez Ramírez, MD Principal Investigator: Sara Pérez Ramírez, MD Hospital Universitario La Paz Not yet recruiting Madrid, Spain Contact: Andrés Redondo, MD Principal Investigator: Andrés Redondo, MD Hospital Universitario Ramon y Cajal Not yet recruiting Madrid, Spain Contact: Eva Guerra, MD Principal Investigator: Eva Guerra, MD H Morales Meseguer Not yet recruiting Murcia, Spain Contact: Helena Garcia, Md Principal Investigator: Helena García, MD Complejo Hospitalario Regional de Málaga Not yet recruiting Málaga, Spain Contact: Maria Jose´ Bermejo, MD Principal Investigator: Maria José Bermejo, MD Hospital Son Llatzer Not yet recruiting Palma De Mallorca, Spain Contact: María Iglesias González, MD Principal Investigator: María Iglesias González, MD Hospital Virgen del Rocio Not yet recruiting Sevilla, Spain Contact: Puri Estévez, MD Principal Investigator: Puri Estévez, MD H La Fe de Valencia Not yet recruiting Valencia, Spain Contact: Ana Santaballa, MD Principal Investigator: Ana Santaballa, MD Hospital Clínico Universitario de Valencia Not yet recruiting Valencia, Spain Contact: José A Pérez Fidalgo, MD Principal Investigator: José A Pérez Fidalgo, MD 收起 <<
NCT02044120	Ewing Sarcoma	Phase 1	Active, not recruiting	April 2021	United States, California ... 展开 >> Children's Hospital of Los Angeles Los Angeles, California, United States, 90027 United States, Maryland National Cancer Institute Bethesda, Maryland, United States, 20892 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48106 United States, Washington Seattle's Children Cancer Center Seattle, Washington, United States, 98101 United Kingdom University College London Hospital London, United Kingdom, W1T 7HA 收起 <<
NCT03025867	-		-	-	-
NCT03307785	Metastatic Cancer ... 展开 >> Advanced Cancer Solid Tumor Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Stage IIIB Non Small Cell Lung Cancer 收起 <<	Phase 1	Recruiting	March 2020	United States, Arizona ... 展开 >> Honor Health Recruiting Scottsdale, Arizona, United States, 85258 Principal Investigator: Jasgit Sachdev, MD United States, California California Cancer Associates for Research and Excellence (cCare) Recruiting Encinitas, California, United States, 92024 Principal Investigator: Alberto Bessudo, MD United States, Florida Florida Cancer Specialist Recruiting Sarasota, Florida, United States, 34232 Principal Investigator: Manish Patel, MD United States, Ohio Gabrail Cancer Center Research Recruiting Canton, Ohio, United States, 44718 Principal Investigator: Nashat Gabrail, MD United States, Tennessee Tennessee Oncology Recruiting Nashville, Tennessee, United States, 37203 Principal Investigator: Erika Hamilton, MD United States, Texas MD Anderson Recruiting Houston, Texas, United States, 77030 Principal Investigator: Timothy Yap, MD 收起 <<
NCT03748641	Metastatic Prostate Cancer	Phase 3	Not yet recruiting	February 25, 2025	-
NCT03651206	Ovarian Carcinosarcoma ... 展开 >> Endometrial Carcinosarcoma 收起 <<	Phase 2 Phase 3	Not yet recruiting	January 2023	-
NCT03695380	OVARIAN CANCER	Phase 1	Not yet recruiting	November 24, 2022	-
NCT03431350	Prostatic Neoplasms, Castratio... 展开 >>n-Resistant 收起 <<	Phase 1 Phase 2	Recruiting	December 31, 2020	United States, Colorado ... 展开 >> The Urology Center of Colorado Recruiting Denver, Colorado, United States, 80211 United States, New York Memorial Sloan Kettering Cancer Center Recruiting Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 United States, Pennsylvania Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 United States, South Carolina MUSC-Hollings Cancer Center Recruiting Charleston, South Carolina, United States, 29425 United States, Texas The University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 United States, Utah University of Utah Huntsman Cancer Institute Withdrawn Salt Lake City, Utah, United States, 84112 United States, Wisconsin University of Wisconsin Carbone Cancer Center Recruiting Madison, Wisconsin, United States, 5379200 Canada, Quebec Centre de Recherche du CHUM Not yet recruiting Montreal, Quebec, Canada, H2X 0A9 Canada British Columbia Cancer Agency Recruiting Vancouver, Canada, V5Z4E6 Israel Asaf Harofe Medical Center Recruiting Beer Yaakov, Israel, 60930 Rambam Medical Center Recruiting Haifa, Israel, 31096 Rabin Medical Center Recruiting Petach Tikva, Israel, 49100 Sheba Medical Center Tel Hashomer Recruiting Ramat Gan, Israel, 52621 Spain Hospital Vall D'Hebron Recruiting Barcelona, Spain, 08035 Hosp. Univ. Fund. Jimenez Diaz Recruiting Madrid, Spain, 28040 Hosp. Univ. Hm Sanchinarro Recruiting Madrid, Spain, 28050 United Kingdom Guy's Hospital Withdrawn London, United Kingdom, SE1 9RT Southampton General Hospital Not yet recruiting Southampton, United Kingdom, SO16 6YD The Royal Marsden NHS Trust Sutton Recruiting Sutton, United Kingdom, SM2 5PT 收起 <<
NCT03516084	Extensive-stage Small Cell Lun... 展开 >>g Cancer 收起 <<	Phase 3	Not yet recruiting	May 2022	-
NCT03551171	Ovarian Cancer	Phase 1	Active, not recruiting	December 30, 2018	China, Beijing ... 展开 >> Beijing Cancer Hospital Beijing, Beijing, China, 100000 China, Guangdong Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510000 China, Heilongjiang Haerbin Medical University Cancer Hospital Harbin, Heilongjiang, China, 150000 China, Hunan Hunan Cancer Hospital Changsha, Hunan, China, 410013 China, Shanghai Fudan University Shanghai Cnacer Center Shanghai, Shanghai, China, 200000 China, Sichuan The West China Second UniversityHospital of Sichuan University Chengdu, Sichuan, China, 610000 收起 <<
NCT03404960	Pancreatic Adenocarcinoma	Phase 1 Phase 2	Recruiting	June 2021	United States, Pennsylvania ... 展开 >> University of Pennsylvania, Abramson Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Danielle Karlson 215-220-9704 danielle.Karlson@uphs.upenn.edu Principal Investigator: Kim Reiss Binder, MD 收起 <<
NCT03602859	Ovarian Cancer	Phase 3	Recruiting	July 31, 2023	United States, Alaska ... 展开 >> Alaska Women's Cancer Care Recruiting Anchorage, Alaska, United States, 99508 United States, Connecticut Hartford Hospital Recruiting Hartford, Connecticut, United States, 06102 United States, Louisiana Women's Cancer Care Recruiting Covington, Louisiana, United States, 70433 Willis-Knighton Cancer Center Recruiting Shreveport, Louisiana, United States, 71103 United States, Maryland Holy Cross Hospital Recruiting Silver Spring, Maryland, United States, 20910 United States, Ohio Aultman Hospital Recruiting Canton, Ohio, United States, 44710 United States, South Dakota Avera Cancer Institute Recruiting Sioux Falls, South Dakota, United States, 57105 United States, Washington Kadlec Regional Medical Center Recruiting Kennewick, Washington, United States, 99336 Swedish Medical Center Recruiting Seattle, Washington, United States, 98104 收起 <<
NCT02476552	Cancer	Phase 1	Completed	-	Netherlands ... 展开 >> The Netherlands Cancer Institute Amsterdam, Netherlands, 1066 CX 收起 <<
NCT02655016	Ovarian Cancer	Phase 3	Active, not recruiting	-	-
NCT02354131	Ovarian Cancer	Phase 1 Phase 2	Active, not recruiting	December 2020	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States Denmark Rigshospitalet Copenhagen, Sjaelland, Denmark, 2100 收起 <<
NCT02354586	Ovarian Cancer	Phase 2	Active, not recruiting	December 2019	-
NCT02657889	Triple Negative Breast Cancer ... 展开 >> Ovarian Cancer Breast Cancer Metastatic Breast Cancer Advanced Breast Cancer Stage IV Breast Cancer Fallopian Tube Cancer Peritoneal Cancer 收起 <<	Phase 1 Phase 2	Active, not recruiting	February 2019	-
NCT03326193	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Primary Peritoneal Carcinoma 收起 <<	Phase 2	Recruiting	September 30, 2021	-
NCT02826512	Breast Cancer	Phase 2	Recruiting	August 2022	Netherlands ... 展开 >> Antoni van Leeuwenhoek Recruiting Amsterdam, Netherlands, 1066 CX Contact: Sabine C Linn, MD +3120512 ext 2951 s.linn@nki.nl Contact: Sonja Vliek, MD s.vliek@nki.nl Principal Investigator: Sabine C Linn, MD Erasmus Medical Center Cancer Institute Not yet recruiting Rotterdam, Netherlands, 3015CE Contact: A Jager, MD a.jager@erasmusmc.nl Principal Investigator: A Jager, MD 收起 <<
NCT02924766	Prostatic Neoplasms	Phase 1	Active, not recruiting	March 7, 2019	United States, California ... 展开 >> West Hollywood, California, United States United States, Kentucky Louisville, Kentucky, United States United States, Oregon Portland, Oregon, United States United States, South Carolina Myrtle Beach, South Carolina, United States Canada, British Columbia Vancouver, British Columbia, Canada Canada, Quebec Montreal, Quebec, Canada 收起 <<
NCT03308942	Lung Neoplasms	Phase 2	Recruiting	May 2020	-
NCT02854436	Prostatic Neoplasms	Phase 2	Recruiting	June 2021	-
NCT03553004	Pancreatic Cancer	Phase 2	Not yet recruiting	February 1, 2025	United States, Kansas ... 展开 >> University of Kansas Cancer Center - Clinical Research Center Not yet recruiting Fairway, Kansas, United States, 66208 Contact: kerry hepler 913-945-7552 ctnursenav@kumc.edu University of Kansas Cancer Center - West Not yet recruiting Kansas City, Kansas, United States, 66112 Contact: Kerry Hepler 913-945-7552 ctnursenav@kumc.edu University of Kansas Cancer Center - Overland Park Not yet recruiting Overland Park, Kansas, United States, 66210 Contact: kerry hepler 913-945-7552 ctnursenav@kumc.edu The University of Kansas Cancer Center Not yet recruiting Westwood, Kansas, United States, 66205 Contact: Kerry Hepler, RN 913-945-7552 ctnursenav@kumc.edu Principal Investigator: Anup Kasi, MD United States, Missouri University of Kansas Cancer Center - North Not yet recruiting Kansas City, Missouri, United States, 64154 Contact: kerr hepler 913-945-7552 ctnursenav@kumc.edu Principal Investigator: Anup Kasi, MD University of Kansas Cancer Center - Lee's Summit Not yet recruiting Lee's Summit, Missouri, United States, 64064 Contact: Kerry Hepler 913-945-7552 ctnursenav@kumc.edu 收起 <<
NCT03207347	Mesothelioma ... 展开 >>Uveal Melanoma Renal Cell Carcinoma Cholangiocarcinoma 收起 <<	Phase 2	Recruiting	December 2022	United States, Florida ... 展开 >> University of Florida Recruiting Gainesville, Florida, United States, 32610 Principal Investigator: Thomas George, MD, FACP 收起 <<
NCT02500901	Metastatic Prostate Cancer	Phase 1	Terminated(Suspended by funder... 展开 >>) 收起 <<	-	United States, Massachusetts ... 展开 >> Tufts Medical Center Boston, Massachusetts, United States, 02111 收起 <<
NCT03759600	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Primary Peritoneal Cancer 收起 <<	Phase 2	Not yet recruiting	November 30, 2020	Japan ... 展开 >> Aichi Cancer Center Hospital Not yet recruiting Nagoya, Aichi, Japan Hirosaki University Hospital Not yet recruiting Hirosaki, Aomori, Japan National Cancer Center Hospital East Not yet recruiting Kashiwa, Chiba, Japan The Jikei University Kashiwa Hospital Not yet recruiting Kashiwa, Chiba, Japan Shikoku Cancer Center Not yet recruiting Matsuyama, Ehime, Japan Ehime University Hospital Not yet recruiting Toon, Ehime, Japan Kurume University Hospital Not yet recruiting Kurume, Fukuoka, Japan Hokkaido University Hospital Not yet recruiting Sapporo, Hokkaido, Japan Sapporo Medical University Hospital Not yet recruiting Sapporo, Hokkaido, Japan Hyogo Cancer Center Not yet recruiting Akashi, Hyogo, Japan Kansai Rosai Hospital Not yet recruiting Amagasaki, Hyogo, Japan Iwate Medical University Hospital Not yet recruiting Morioka, Iwate, Japan Tokai University Hospital Not yet recruiting Isehara, Kanagawa, Japan Nippon Medical School Musashi Kosugi Hospital Not yet recruiting Kawasaki, Kanagawa, Japan Mie University Hospital Not yet recruiting Tsu, Mie, Japan Tohoku University Hospital Not yet recruiting Sendai, Miyagi, Japan University of the Ryukyus Hospital Not yet recruiting Nakagami-gun, Okinawa, Japan Kindai University Hospital Not yet recruiting Osakasayama, Osaka, Japan Saitama Medical University International Medical Center Not yet recruiting Hidaka, Saitama, Japan Shizuoka Cancer Center Not yet recruiting Nagaizumi-cho, Shizuoka, Japan National Cancer Center Hospital Not yet recruiting Chuo-ku, Tokyo, Japan Cancer Institute Hospital Not yet recruiting Koto-ku, Tokyo, Japan The Jikei University Hospital Not yet recruiting Minato-ku, Tokyo, Japan Toho University Omori Medical Center Not yet recruiting Ota-ku, Tokyo, Japan Keio University Hospital Not yet recruiting Shinjuku-ku, Tokyo, Japan Chiba Cancer Center Not yet recruiting Chiba, Japan Gifu University Hospital Not yet recruiting Gifu, Japan Kagoshima City Hospital Not yet recruiting Kagoshima, Japan Kyoto University Hospital Not yet recruiting Kyoto, Japan Nagasaki University Hospital Not yet recruiting Nagasaki, Japan Niigata University Medical & Dental Hospital Not yet recruiting Niigata, Japan 收起 <<
NCT03497429	Advanced Solid Tumors	Phase 1	Active, not recruiting	August 31, 2019	Japan ... 展开 >> National Cancer Center Hospital Chuo-ku, Tokyo, Japan 收起 <<
NCT03359850	Solid Tumor H... 展开 >>epatic Impairment 收起 <<	Phase 1	Recruiting	February 2019	United States, California ... 展开 >> University of Southern California Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90089 Principal Investigator: Anthony El-Khoueiry, MD United States, Colorado University of Colorado Anschutz Medical Campus Recruiting Aurora, Colorado, United States, 80045 Principal Investigator: Cindy O' Bryant, MD United States, Georgia Winship Cancer Institute of Emory University Recruiting Atlanta, Georgia, United States, 30322 Principal Investigator: Akce Mehmet United States, Texas MD Anderson Recruiting Houston, Texas, United States, 77030 Principal Investigator: Sirena Piha-Paul, MD 收起 <<
NCT01110603	Cancer: Solid Tumors	Phase 1	Terminated	-	-
NCT01847274	Platinum Sensitive Ovarian Can... 展开 >>cer 收起 <<	Phase 3	Completed	-	-
NCT03586661	Deleterious BRCA1 Gene Mutatio... 展开 >>n Deleterious BRCA2 Gene Mutation Endometrial Adenocarcinoma High Grade Ovarian Serous Adenocarcinoma Primary Peritoneal High Grade Serous Adenocarcinoma Recurrent Endometrial Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma 收起 <<	Phase 1	Not yet recruiting	October 2020	United States, Texas ... 展开 >> M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: N. swestin@mdanderson.org 收起 <<
NCT03016338	Endometrial Cancer	Phase 2	Recruiting	September 2022	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre Recruiting Calgary, Alberta, Canada, T2N 4N2 Contact: Prafull Ghatage, M.D. 403-521-3721 Principal Investigator: Prafull Ghatage Canada, Ontario Juravinski Cancer Centre Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Waldo Jimenez, M.D. 905-387-9495 Principal Investigator: Waldo Jimenez, M.D. Cancer Centre of Southeastern Ontario at Kingston Recruiting Kingston, Ontario, Canada, K7L 5P9 Contact: Jim Biagi, M.D. 613-44-2630 Principal Investigator: Jim Biagi, M.D. London Regional Cancer Centre Recruiting London, Ontario, Canada, N6A 4L6 Contact: Stephen Welch, M.D. 519-685-8640 Sunnybrook Research Institute, Sunnybrook Health Sciences Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Helen MacKay, M.D. 416-480-5145 Principal Investigator: Helen MacKay, M.D. Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 1M9 Contact: Stephanie Lheureux, M.D. 416-946-2818 Principal Investigator: Stephanie Lheureux, M.D. Canada, Quebec McGill University Health Centre - Glen Site Recruiting Montréal, Quebec, Canada, H3A 3J1 Contact: Lucy Gilbert, M.D. 514-934-1934 ext 34049 Principal Investigator: Lucy Gilbert, M.D. 收起 <<
NCT03154281	Breast Cancer ... 展开 >> Ovarian Cancer 收起 <<	Phase 1	Recruiting	June 2021	United States, South Dakota ... 展开 >> Avera Cancer Institute Recruiting Sioux Falls, South Dakota, United States, 57105 Contact: Brian Leyland-Jones, MD 605-322-6900 brian.leylandjones@avera.org 收起 <<
NCT03329001	Solid Tumor	Phase 1	Recruiting	December 2019	United States, California ... 展开 >> California Cancer Center for Research Excellence cCARE Recruiting Encinitas, California, United States, 92024 Principal Investigator: Alberto Bessudo, MD United States, Georgia Winship Cancer Institute of Emory University Recruiting Atlanta, Georgia, United States, 30322 Principal Investigator: R. Donald Harvey, PharmD United States, Tennessee Tennesse Oncology (SCRI) Recruiting Nashville, Tennessee, United States, 37203 Principal Investigator: Erika Hamilton, MD United States, Texas MD Anderson Recruiting Houston, Texas, United States, 77030 Principal Investigator: Sarina Piha-Paul, MD START- South Texas Accelerated Research Therapeutics, LLC Recruiting San Antonio, Texas, United States, 78229 Principal Investigator: Amita Patnaik, MD 收起 <<
NCT01905592	Carcinoma of Breast ... 展开 >> Human Epidermal Growth Factor 2 Negative Carcinoma of Breast BRCA1 Gene Mutation BRCA2 Gene Mutation 收起 <<	Phase 3	Active, not recruiting	May 2018	-
NCT03425201	Urothelial Cancer	Phase 1 Phase 2	Not yet recruiting	December 2019	Spain ... 展开 >> ICO Badalona Badalona, Spain Hospital Clinic Barcelona, Spain Hospital de la Santa Creu i Sant Pau Barcelona, Spain ICO L'Hospitalet L'Hospitalet De Llobregat, Spain ICO L'Hospitalet Not yet recruiting L'Hospitalet De Llobregat, Spain Contact: Nuria Sala Hospital 12 de Octubre Madrid, Spain Althaia Xarxa Not yet recruiting Manresa, Spain Contact: Montserrat Domenech Instituto Valenciano de Oncología Valencia, Spain 收起 <<
NCT03759587	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Primary Peritoneal Cancer 收起 <<	Phase 2	Not yet recruiting	April 30, 2021	Japan ... 展开 >> Aichi Cancer Center Hospital Not yet recruiting Nagoya, Aichi, Japan Hirosaki University Hospital Not yet recruiting Hirosaki, Aomori, Japan Shikoku Cancer Center Not yet recruiting Matsuyama, Ehime, Japan Ehime University Hospital Not yet recruiting Toon, Ehime, Japan Kurume University Hospital Not yet recruiting Kurume, Fukuoka, Japan Hokkaido University Hospital Not yet recruiting Sapporo, Hokkaido, Japan Sapporo Medical University Hospital Not yet recruiting Sapporo, Hokkaido, Japan Hyogo Cancer Center Not yet recruiting Akashi, Hyogo, Japan Kansai Rosai Hospital Not yet recruiting Amagasaki, Hyogo, Japan Iwate Medical University Hospital Not yet recruiting Morioka, Iwate, Japan Tokai University Hospital Not yet recruiting Isehara, Kanagawa, Japan Nippon Medical School Musashi Kosugi Hospital Not yet recruiting Kawasaki, Kanagawa, Japan Mie University Hospital Not yet recruiting Tsu, Mie, Japan Tohoku University Hospital Not yet recruiting Sendai, Miyagi, Japan University of the Ryukyus Hospital Not yet recruiting Nakagami-gun, Okinawa, Japan Kindai University Hospital Not yet recruiting Osakasayama, Osaka, Japan Saitama Medical University International Medical Center Not yet recruiting Hidaka, Saitama, Japan Shizuoka Cancer Center Not yet recruiting Nagaizumi-cho, Shizuoka, Japan National Cancer Center Hospital Not yet recruiting Chuo-ku, Tokyo, Japan Cancer Institute Hospital Not yet recruiting Koto-ku, Tokyo, Japan The Jikei University Hospital Not yet recruiting Minato-ku, Tokyo, Japan Keio University Hospital Not yet recruiting Shinjuku-ku, Tokyo, Japan Chiba Cancer Center Not yet recruiting Chiba, Japan Kagoshima City Hospital Not yet recruiting Kagoshima, Japan Kyoto University Hospital Not yet recruiting Kyoto, Japan Nagasaki University Hospital Not yet recruiting Nagasaki, Japan Niigata University Medical & Dental Hospital Not yet recruiting Niigata, Japan 收起 <<
NCT03076203	Prostate Carcinoma Metastatic ... 展开 >>to the Bone Stage IV Prostate Adenocarcinoma Hormone-refractory Prostate Cancer 收起 <<	Phase 1	Recruiting	November 2021	United States, Pennsylvania ... 展开 >> Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: William Kelly, DO william.kelly@jefferson.edu 收起 <<
NCT03209401	Solid Tumor, Adult ... 展开 >> Homologous Recombination Deficiency 收起 <<	Phase 1	Recruiting	July 2022	United States, District of Col... 展开 >>umbia Lombardi Comprehensive Cancer Center Recruiting Washington, District of Columbia, United States, 20057 Contact: Laura Macke, RN 202-687-2111 lab228@georgetown.edu Principal Investigator: Michael Pishvaian, MD, PhD Principal Investigator: Claudine Isaacs, MD 收起 <<
NCT03601923	Pancreatic Cancer	Phase 2	Recruiting	February 28, 2025	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: James Cleary, MD, PhD 617-632-6353 JCLEARY@PARTNERS.ORG Principal Investigator: James Cleary, MD, PhD 收起 <<
NCT03752216	Ovarian Cancer	Phase 4	Not yet recruiting	November 2021	France ... 展开 >> Institut Sainte-Catherine Not yet recruiting Avignon, France, 84918 Contact: Julien GRENIER CHRU Jean Minjoz Not yet recruiting Besançon, France, 25030 Contact: Elsa KALBACHER Clinique Tivoli Not yet recruiting Bordeaux, France, 33000 Contact: Delphine GARBAY-DECOOPMAN Institut Bergonié Not yet recruiting Bordeaux, France, 33076 Contact: Camille CHAKIBA Hôpital Fleyriat Not yet recruiting Bourg-en-bresse, France, 01012 Contact: Hubert ORFEUVRE Centre François Baclesse Not yet recruiting Caen, France, 14000 Contact: Pierre-Emmanuel BRACHET ROC 37 Société de Recherche Oncologique Clinique 37 Not yet recruiting Chambray-lès-Tours, France, 37170 Contact: Pierre COMBE Centre Jean Perrin Not yet recruiting Clermont-Ferrand, France, 63000 Contact: Marie Ange MOURET-REYNIER Centre Léon Bérard Not yet recruiting Lyon, France, 69373 Contact: Isabelle RAY-COQUARD Hôpital Privé Jean Mermoz Not yet recruiting Lyon, France, 69373 Contact: Olfa DERBEL Institut Paoli Calmettes Not yet recruiting Marseille, France, 13009 Contact: Magali PROVANSAL CH Mont-de-Marsan Not yet recruiting Mont-de-marsan, France, 40024 Contact: Jérôme DAUBA ICM Val d'Aurelle Not yet recruiting Montpellier, France, 34298 Contact: Michel FABBRO ORACLE - Centre d'Oncologie de Gentilly Not yet recruiting Nancy, France, 54100 Contact: Célia ROEMER-BECUWE Centre Antoine Lacassagne Not yet recruiting Nice, France, 06189 Contact: Philippe FOLLANA Centre ONCOGARD - Institut de Cancérologie du Gard Not yet recruiting Nimes, France, 30029 Contact: Eric LEGOUFFE Hôpital Cochin Not yet recruiting Paris, France, 75014 Contact: Jérôme ALEXANDRE Groupe Hospitalier Diaconesses-Croix Saint Simon Not yet recruiting Paris, France, 75020 Contact: Frédéric SELLE Centre CARIO - HPCA Not yet recruiting Plérin, France, 22190 Contact: Anne-Claire HARDY-BESSARD Clinique Mutualiste de l'Estuaire Not yet recruiting Saint-nazaire, France, 44600 Contact: Valérie DELECROIX Institut de Cancérologie Lucien Neuwirth Not yet recruiting Saint-Priest-en-Jarez, France, 42271 Contact: Olivier COLLARD Hôpitaux Universitaires de Strasbourg Not yet recruiting Strasbourg, France, 67000 Contact: Jean-Emmanuel KURTZ Institut Claudius Regaud Not yet recruiting Toulouse, France, 31059 Contact: Laurence GLADIEFF Clinique Pasteur - ONCOSUD Not yet recruiting Toulouse, France, 31076 Contact: Raymond DESPAX Gustave Roussy Not yet recruiting Villejuif, France, 94805 Contact: Fanny POMMERET 收起 <<
NCT03644342	Metastatic Carcinoma of the Ce... 展开 >>rvix 收起 <<	Phase 1 Phase 2	Not yet recruiting	March 2, 2026	United States, Texas ... 展开 >> Baylor College of Medicine Not yet recruiting Houston, Texas, United States, 77030 Contact: Michelle S Ludwig, MD, MPH, PhD 713-566-3757 Michelle.Ludwig@bcm.edu Harris Health System - Smith Clinic Houston, Texas, United States, 77054 收起 <<
NCT01294735	Recurrence of Solid Tumor ... 展开 >> Glioblastoma Multiforme Melanoma 收起 <<	Phase 1	Completed	-	-
NCT03368729	Metastatic Breast Cancer ... 展开 >> HER2 Positive Breast Carcinoma 收起 <<	Phase 1 Phase 2	Not yet recruiting	November 1, 2021	United States, Alabama ... 展开 >> University of Alabama at Birmingham Not yet recruiting Birmingham, Alabama, United States, 35294 Contact: Erica Stringer-Reasor, M.D. 205-934-2992 strinem@uab.edu 收起 <<
NCT01227941	Ovarian Cancer	Phase 1	Terminated	-	-
NCT03329937	Human Epidermal Growth Factor ... 展开 >>2 Negative Carcinoma of Breast BRCA1 Gene Mutation BRCA2 Gene Mutation 收起 <<	Phase 1	Recruiting	March 2020	United States, California ... 展开 >> Pacific Shores Medical Oncology Recruiting Long Beach, California, United States, 90808 United States, Florida Florida Cancer Specialists- South Recruiting Fort Myers, Florida, United States, 33901 Memorial Health Care System Recruiting Pembroke, Florida, United States, 33028 Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at John Hopkins Recruiting Baltimore, Maryland, United States, 21231 United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 United States, New York Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029 United States, Oregon Providence Portland Medical center Recruiting Portland, Oregon, United States, 97231 United States, Tennessee Tennessee Oncology Recruiting Nashville, Tennessee, United States, 37203 United States, Texas Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 收起 <<
NCT00749502	Solid Tumors ... 展开 >>Chronic Lymphocytic Leukemia T-cell-prolymphocytic Leukemia 收起 <<	Phase 1	Completed	-	-
NCT01244009	Lymphoma Mant... 展开 >>le-Cell 收起 <<	Phase 2	Withdrawn(Sponsor decision)	August 2013	-
NCT01226901	Neoplasms Sol... 展开 >>id Tumors 收起 <<	Phase 1	Terminated	-	-

尼拉帕尼 /Niraparib {[allProObj[0].p_purity_real_show]}

Niraparib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Niraparib 质控信息

Niraparib 生物活性

Niraparib 细胞研究

Niraparib 动物研究

Niraparib 临床研究

Niraparib 参考文献

Niraparib 实验方案

Niraparib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

尼拉帕尼 /Niraparib {[allProObj[0].p_purity_real_show]}

Niraparib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Niraparib 质控信息

Niraparib 生物活性

Niraparib 细胞研究

Niraparib 动物研究

Niraparib 临床研究

Niraparib 参考文献

Niraparib 实验方案

Niraparib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Niraparib 纯度/质量文件产品仅供科研